A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c

NCT00215566 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Irritable Bowel Syndrome With Constipation
Irritable Bowel Syndrome

Interventions

DRUG: DDP733

Sponsor

Dynogen Pharmaceuticals